Precipio ( (PRPO) ) has released its Q3 earnings. Here is a breakdown of the information Precipio presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Precipio, Inc. is a healthcare biotechnology company focused on cancer diagnostics, aiming to address cancer misdiagnoses through innovative diagnostic products and services. In its latest earnings report, Precipio highlighted a significant improvement in its financial performance, with a notable increase in net sales and a reduction in net losses compared to the previous year. The company reported net sales of $6.8 million for the third quarter of 2025, up from $5.2 million in the same period last year, driven by both service and product revenue growth. Despite an operating loss of $61,000, this marks a substantial improvement from the $597,000 loss recorded in the third quarter of 2024. The company also benefited from a gain on the settlement of liabilities and an Employee Retention Credit, contributing to a narrower net loss of $79,000 for the quarter. Looking ahead, Precipio remains focused on achieving its business plan, generating additional revenue, and securing financing to meet its obligations, with management expressing cautious optimism about the company’s ability to continue as a going concern.